C12N2310/316 - CPC Classification Index

#1

20260092283

2026-04-02

COMPOSITIONS AND METHODS FOR THE TREATMENT OF COMPLICATIONS AND DISORDERS RELATING TO VON WILLEBRAND FACTOR

#2

20250376683

2025-12-11

Selective Antisense Compounds and Uses Thereof

#3

20250313846

2025-10-09

PRODUCTS AND COMPOSITIONS

#4

20250243491

2025-07-31

PNPLA3-TARGETING SHORT INTERFERING RNA (SIRNA) MOLECULES AND USES THEREOF

#5

20250059547

2025-02-20

NLRP3 oligonucleotide for use in preventing and/or treating an inflammatory disease

#6

20250059544

2025-02-20

ANTISENSE OLIGONUCLEOTIDES (ASOS) THAT SUPPRESS SARS-COV-2 REPLICATION

#7

20240415980

2024-12-19

CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR KNOCKING OUT C5

#8

20240368592

2024-11-07

Selective Antisense Compounds and Uses Thereof

#9

20240309387

2024-09-19

TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#10

20240294920

2024-09-05

MODULATION OF NOX4 EXPRESSION

#11

20240141346

2024-05-02

TARGETED INHIBITION USING ENGINEERED OLIGONUCLEOTIDES

#12

20240141343

2024-05-02

Selective Antisense Compounds and Uses Thereof

#13

20240067972

2024-02-29

DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#14

20240011027

2024-01-11

METHODS AND COMPOSITIONS FOR RESTORING STMN2 LEVELS

#15

20230295626

2023-09-21

Targeted inhibition using engineered oligonucleotides

#16

20230242909

2023-08-03

METHODS AND COMPOSITIONS FOR NEUROPROTECTION

#17

20230235321

2023-07-27

GENE EDITING TO IMPROVE JOINT FUNCTION

#18

20230132602

2023-05-04

Targeted Inhibition Using Engineered Oligonucleotides

#19

20230113863

2023-04-13

Selective Antisense Compounds and Uses Thereof

#20

20220213480

2022-07-07

Targeted inhibition using engineered oligonucleotides

#21

20220195439

2022-06-23

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

#22

20210254076

2021-08-19

TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#23

20210238591

2021-08-05

Selective antisense compounds and uses thereof

#24

20210147838

2021-05-20

Selective Antisense Compounds and Uses Thereof

#25

20200392511

2020-12-17

TMPRSS6 iRNA compositions and methods of use thereof

#26

20200291407

2020-09-17

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

#27

20200165612

2020-05-28

Compositions and methods for the treatment of complications and disorders relating to Von Willebrand Factor

#28

20200157537

2020-05-21

Modulating RNA Interactions with Polycomb Repressive Complex 1 (PRC1)

#29

20190338281

2019-11-07

SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF

#30

20190211341

2019-07-11

TMPRSS6 iRNA compositions and methods of use thereof

#31

20190040394

2019-02-07

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

#32

20180208929

2018-07-26

Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor

#33

20180201931

2018-07-19

Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)

#34

20180087058

2018-03-29

TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#35

20170355995

2017-12-14

Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21

#36

20170226516

2017-08-10

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

#37

20170073681

2017-03-16

RNAi-Mediated Inhibition of Frizzled Related Protein-1 for Treatment of Glaucoma

#38

20160168568

2016-06-16

Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ)

#39

20160145629

2016-05-26

TMPRSS6 iRNA compositions and methods of use thereof

#40

20150299701

2015-10-22

Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor

#41

20150259685

2015-09-17

Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2

#42

20150259681

2015-09-17

Oligomeric compounds comprising tricyclic nucleosides and methods for their use

#43

20150232850

2015-08-20

Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3)

#44

20150225725

2015-08-13

Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21

#45

20150225724

2015-08-13

Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)

#46

20150197750

2015-07-16

Treatment of ‘IQ motif containing gtpase activating protein’ (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP

#47

20150094358

2015-04-02

Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF

#48

20150080456

2015-03-19

Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1

#49

20140323707

2014-10-30

Selective antisense compounds and uses thereof

#50

20140309279

2014-10-16

Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereof

#51

20130184325

2013-07-18

TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO HGF

#52

20130035373

2013-02-07

Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21

#53

20120329855

2012-12-27

Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF

#54

20120329727

2012-12-27

Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2

#55

20120289583

2012-11-15

TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)

#56

20120264812

2012-10-18

Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1

#57

20120178795

2012-07-12

RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

#58

20120142610

2012-06-07

Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP

#59

20120129917

2012-05-24

Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin

#60

20120064048

2012-03-15

Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor

#61

20110319476

2011-12-29

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

#62

20110190381

2011-08-04

RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

#63

20110092570

2011-04-21

Oligomeric compounds comprising tricyclic nucelosides and methods for their use

#64

20110065778

2011-03-17

RNA interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (siNA)

#65

20100151458

2010-06-17

OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA

#66

20100099750

2010-04-22

RNA interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (siNA)

#67

20090270486

2009-10-29

HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF

#68

20090099120

2009-04-16

RNA interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (siNA)

#69

20070270360

2007-11-22

Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid

#70

20070161596

2007-07-12

RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)

#71

20060223773

2006-10-05

RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

#72

20060160757

2006-07-20

RNA interference mediated inhibition hairless of (HR) gene expression using short interfering nucleic acid (siNA)

#73

20050209182

2005-09-22

Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity

#74

20050209179

2005-09-22

RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)

#75

20050203040

2005-09-15

RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)

#76

20050159384

2005-07-21

Human RNase III and compositions and uses thereof

#77

20050048529

2005-03-03

RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)

#78

20050014172

2005-01-20

RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)